News | November 25, 2021
Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
It is estimated that one-third of our country’s population has some form of these disorders
A first for the Asian market, addressing the health spends needs of over 200 million households.
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Vakrangee’s distribution network across rural India will help penetrate underserved markets
Subscribe To Our Newsletter & Stay Updated
